CD274 and neoplasm: In T-cells, administering lenalidomide results in enhanced costimulation signaling (upregulation of CD80/CD86, CD1c, CD40, and downregulation of PD-L1) and increased IL-2 secretion, so that tumor cells will be more visible to the surrounding immune effector cells.